Ab&B fortifies for battle over China’s vaccine market 流感疫苗企業中慧元通招股 持續虧損陷商業化困局
With proceeds from a Hong Kong IPO, the loss-making biotech is bidding for a piece of China’s fiercely competitive market for flu and human rabies vaccines. 中慧元通擁有兩款核心產品，分別是2023年5月獲批上市的四價流感病毒亞單位疫苗，以及即將進入III期臨床試驗的凍干人用狂犬病疫苗。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.